Jacobio Pharmaceuticals Group Co., Ltd. (SEHK: 1167)
Health Care · Biotechnology · CN
HK$5.27
-0.28% today · -36.9% 1Y
Jacobio Pharmaceuticals Group Co., Ltd. (SEHK: 1167) operates in the Biotechnology industry within the Health Care sector. The company is valued at $526.02M and employs 67 people.
Over the last twelve months the share price has lost 36.9%, trading between 3.98 and 11.80.
Tweenvest scores Jacobio Pharmaceuticals Group Co., Ltd. across four factors: quality 32/100, value 65/100, growth 0/100. Its strongest factor is value.
1167 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $526.02M
- Revenue (TTM)
- $7.65M
- P/E
- —
- EPS
- -0.19
- Dividend yield
- —
- Beta (5Y)
- 0.30
- 52-week high
- HK$11.80
- 52-week low
- HK$3.98
- Avg volume (3M)
- —
- Shares outstanding
- 783.29M
- Employees
- 67
- Next earnings
- —
About Jacobio Pharmaceuticals Group Co., Ltd.
Jacobio Pharmaceuticals Group Co., Ltd. is a clinical-stage pharmaceutical firm specializing in the proprietary discovery and development of oncology therapies. Its primary drug development initiatives feature two clinical-stage allosteric Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitors, JAB-3312 and JAB-3068, which are being investigated for esophageal cancer. Also in development is JAB-8263, a small molecule designed to inhibit BET family proteins that regulate MYC transcription, aiming to treat a range of cancers, alongside JAB-21822, an oral small molecule specifically targeting the mutant KRAS G12C protein. Jacobio is further advancing JAB-BX102, a humanized inhibitory antibody against human CD73, intended for treating PD-1 resistant cancers. Other pipeline assets include JAB-6343, an inhibitor targeting fibroblast growth factor receptor 4 for advanced hepatocellular carcinoma exhibiting FGF19 overexpression; JAB-2485, an aurora A kinase inhibitor for solid tumors; JAB-24114, which targets a tumor metabolic pathway for solid tumor treatment; and JAB-BX300, a molecular antibody designed to target the RAS pathway for pancreatic and other solid tumors with KRAS mutations. The company maintains a strategic partnership with AbbVie Ireland Unlimited Company for the development and commercialization of SHP2 inhibitors. Established in 2015, Jacobio Pharmaceuticals is headquartered in Beijing, China.
- ISIN
- KYG4987A1094
- Founded
- 2015
- Listed since
- Dec 21, 2020
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.83 | +14.36% |
Figures last refreshed Aug 18, 2026.